For adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma
How may I benefit from ADCETRIS?
Before making decisions about your treatment, see how adults with classical Hodgkin lymphoma have responded to ADCETRIS.
*Amina was compensated by Pfizer for participating in this campaign.
Select each tab to see ADCETRIS study results for people with certain types of classical Hodgkin lymphoma
Previously untreated
Relapsed
After stem cell transplant
ECHELON-1 study design information
ECHELON-1 was a large, international, clinical study of 1334 people that compared the effectiveness and safety of ADCETRIS plus AVD with ABVD chemotherapy in patients with previously untreated Stage 3 and 4 classical Hodgkin lymphoma.
- 664 people were assigned to receive ADCETRIS plus AVD chemotherapy every 2 weeks for up to 12 doses
- 670 people were assigned to receive ABVD chemotherapy every 2 weeks for up to 6 cycles
Researchers reviewed the results of these treatments at approximately 2 years and collected data about long-term results at 6 years.
Select the button above to view side effects.
Study results
APPROXIMATELY 6 YEARS AFTER TREATMENT
Overall survival rate was higher with ADCETRIS plus AVD
compared to ABVD chemotherapy
- The following data represent the overall survival that was observed at 6 years
- Overall survival is the length of time, from the start of treatment, that patients are still alive
- These data are the secondary endpoint in the study
- The median follow-up time was 6.1 years
- About 94% of adults treated with ADCETRIS plus AVD, and about 89% of adults treated with ABVD, were still alive at 6 years
After 2 years of follow up
ADCETRIS plus AVD was more effective than ABVD
- The following data represent the modified progression-free survival that was observed at 2 years
- Modified progression-free survival means the length of time during and after treatment a patient lives without cancer progression, death, or receiving another cancer treatment
- These data are the primary endpoint in the study, and these results were used to help support the FDA approval of ADCETRIS plus AVD
- The median follow-up time was just over 2 years (24.6 months)
- About 82% of adults treated with ADCETRIS plus AVD did not have their cancer grow or spread, need additional anticancer therapy, or die compared to about 77% of adults treated with traditional ABVD chemotherapy
For additional 6-year follow-up data, review the Treatment Decision Guide, which can help you feel confident discussing options with your doctor.
Tell your doctor about any side effect concerns you have
Your doctor should prescribe granulocyte colony-stimulating factor (G-CSF) along with your ADCETRIS treatment right at the start. G-CSF is a medication that may help reduce the chance of neutropenia (low white blood cell count).
Don’t stop, change, or delay your ADCETRIS plus AVD treatment unless directed by your doctor. Your doctor may take additional steps to help manage side effects, including:
- Reducing your ADCETRIS dosage, or delaying your next dose, until symptoms improve
- Stopping ADCETRIS completely if side effects are severe or do not improve
Glossary
ABVD: A combination of 4 chemotherapies—Adriamycin, bleomycin, vinblastine, and dacarbazine.
AVD: A combination of 3 chemotherapies—Adriamycin, vinblastine, and dacarbazine.
FDA: Food and Drug Administration.
G-CSF: Granulocyte colony-stimulating factor, a medication that can help boost white blood cell count.
Median: The middle number in a list of numbers.
Neutropenia: Having low levels of a type of white blood cell called neutrophils that help your immune system. You could have a higher chance of getting an infection.
Overall survival: The length of time that patients remain alive after starting study treatment.
Amina’s treatment journey
Amina knew something was wrong and spoke up. Listening to herself and her body is what helped Amina find out she had Stage 3 classical Hodgkin lymphoma. Throughout this challenging diagnosis, she found support and encouragement from her family, friends, and healthcare team.
ADCETRIS will not work for everyone.
The science of ADCETRIS treatment
ADCETRIS is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker.
Antibody
An antibody that finds CD30, a protein on the surface of certain cells. Antibodies are proteins made by the body’s immune system. The antibody that makes up ADCETRIS is made in a laboratory.
Drug
A drug that is designed to cause cell death.
Linker
A linker that attaches the drug to the antibody and is designed to release the drug inside the cell.
How does ADCETRIS work?
Step 1
ADCETRIS aims to attach to cells that have a protein on their surface called CD30.
Step 2
Once attached, ADCETRIS is brought into the cell and released.
Step 3
The drug stops the cell from being able to grow and divide, causing the cell to die.
CD30 is found on classical Hodgkin lymphoma cells and not commonly found on healthy cells. Even though ADCETRIS is a CD30-directed therapy, it can still harm normal cells and cause side effects. Talk to your doctor if you have questions about possible side effects.